Daptomycin is a novel cyclic lipopeptide antibiotic that provides rapid bactericidal activity against gram-positive pathogens in vitro, including methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus, vancomycin-resistant S. aureus, penicillin-resistant Streptococcus pneumoniae, and ampicillin-and vancomycin-resistant enterococci. The United States Food and Drug Administration recently approved daptomycin for treatment of complicated skin and skin-structure infections. Its efficacy in the treatment of more-serious infections (e.g., staphylococcal bacteremia) is under investigation. As an intravenous agent that is administered once per day, it offers a convenient regimen for therapy that is continued after discharge, with a side effect profile that appears minimal and manageable. Spontaneous acquisition of resistance in vitro is rare, and hopefully this characteristic will extrapolate into the clinical setting. The rapid bactericidal activity, low potential for resistance, and promising safety profile associated with this agent will make it a useful addition to our growing armamentarium of antibiotics active against gram-positive pathogens.
Fundamental requisites of the ideal antibiotic, especially one that targets drug-resistant pathogens, include bactericidal activity, consistent potency with clinically proven activity, low potential for the development of resistance, availability in both intravenous and oral formulations, convenient dosing, low potential for adverse events, no significant drug interactions, and low cost. Although a few agents that have recently been developed to treat drug-resistant gram-positive bacterial infections appear to achieve some of these goals, shortcomings remain. Linezolid (Zyvox; Pfizer), introduced in the United States in 2000, and quinupristin-dalfopristin (Synercid; Monarch Pharmaceuticals), introduced in 1999, have proven clinically useful in the treatment of drug-resistant gram-positive bacterial infections, but both of these agents have intrinsic qualities that make them less than ideal antimicrobials under certain circumstances [1] . Quinupristin-dalfopristin is available only for intravenous administration, has infusion-related side effects, and has the potential for drug-drug interactions [1] . Linezolid is bacteriostatic against staphylococci and enterococci, and concerns have been raised regarding long-term (12-week) administration of the drug because of potential bone marrow toxicity [1] . Vancomycin remains the workhorse for treating most drugresistant gram-positive bacterial infections; however, concerns over increases in the rates of resistance to this agent (e.g., in vancomycin-resistant Enterococcus species and Staphylococcus aureus), combined with its pharmacodynamic and clinical shortcomings and the increasingly important role of grampositive bacterial infections in clinical medicine, have motivated the development of newer agents.
Daptomycin (Cubicin; Cubist Pharmaceuticals) (table 1) is a novel antibiotic that may be a step closer, in some respects, to the ideal agent for treating drug-resistant gram-positive bacterial infections. Daptomycin was discovered by Eli Lilly in the early 1980s (and known then as LY146032); however, concerns Mechanism of action Binds to the cell membrane via calcium-dependent insertion of its lipid tail, forming an ion-conduction structure that is hypothesized to rapidly depolarize the cell membrane via an efflux of potassium (and possibly other ions) that is associated with a disruption of DNA, RNA, and protein synthesis and with cellular death.
Pharmacokinetics
Intravenous, linear kinetics through 6 mg/kg; AUC 0-24 values for 4 mg/kg, 6 mg/kg, and 8 mg/kg doses in healthy volunteers are 494 mg*h/mL, 747mg*h/mL, and 1130 mg*h/mL, with corresponding C max values of 57.8 mg/mL, 98.6 mg/mL, and 133 mg/mL; T 1/2 8-9 h; 92% protein bound with very low volume of distribution (0.1 L/kg); 78% excreted via the kidney, two-thirds (∼52% of total dose) as intact drug; not extensively metabolized.
Pharmacodynamics
Rapidly bactericidal in a concentration-dependent manner with a significant postantibiotic effect.
In vitro spectrum Gram-positive pathogens, including methicillin- [4] . Cubist Pharmaceuticals has also conducted the following active, completed, or terminated studies with daptomycin: gram-positive bacteremia and endocarditis, vancomycin-resistant enterococcal infections, urinary tract infections, and community-acquired pneumonia. Daptomycin is only available as an intravenous agent; an oral formulation that used Emisphere carrier molecules (Emisphere Technologies) was under study, but the bioavailability did not approach clinically relevant levels (data on file, Cubist Pharmaceuticals) [5] .
STRUCTURE AND MECHANISM OF ACTION
Daptomycin is a cyclic lipopeptide derived from Streptomyces roseosporus as a fermentation product [2, 3] . It consists of a highly lipophilic decanoic acid side chain linked to the Nterminal tryptophan of a cyclic 13-member peptide (figure 1) [2, 3] . The precise mechanism of action is not completely understood; it is known to act at the cytoplasmic membrane, binding to the membrane via a calcium-dependent insertion of its lipid tail [2, 3, [5] [6] [7] . It is only active against gram-positive bacteria because it is unable to penetrate the outer membrane of gram-negative bacteria [2, 3, 5] . Current understanding of its mechanism of action suggests that it forms an ion-conduction structure, resulting in an efflux of potassium (and possibly other ions) with an associated dissipation of the ion concentration gradient [5] . Large molecules are not released from the cytoplasm [5] . Cell death occurs as a result of widespread dysfunction of macromolecular synthesis, including synthesis of DNA, RNA, and proteins; cell lysis does not occur [5] . Although inhibition of lipoteichoic acid synthesis has also been considered as a possible mechanism of action, recent studies do not support this hypothesis [6] . Notably, the activity of daptomycin is dependent on the presence of calcium ions, which directly impacts the conditions required for in vitro susceptibility testing [9] .
IN VITRO ACTIVITY
Daptomycin has rapid concentration-dependent bactericidal activity against most gram-positive pathogens, including those with multidrug resistance [2, 3, 5, 7] . It is not active against gram-negative organisms because of its inability to penetrate the outer membrane of the bacteria [2, 3, 5] . The activity of daptomycin is dependent on the concentration of calcium in the growth medium; it is 2-4-fold more active in MuellerHinton media supplemented to 50 mg Ca 2+ per mL, compared with the standard 20-25 mg Ca 2+ per mL recommended by the NCCLS [8, 9] . Notably, the MICs of daptomycin were closely comparable for resistant and susceptible isolates of S. aureus, Streptococcus pneumoniae, Enterococcus faecium, and E. faecalis, as would be expected with its novel mechanism of action [8] [9] [10] [11] [12] [13] [14] [15] (table 2) . In the limited number of S. aureus isolates tested that were classified as either intermediately susceptible or resistant to vancomycin, daptomycin retained activity [5, [12] [13] [14] [15] [16] [17] . The MIC of daptomycin for determining susceptibility is р1 mg/mL for S. aureus (both methicillin-resistant and methicillinsusceptible strains), S. pyogenes, S. agalactiae, and S. dysgalactiae subspecies equisimilis, and it is р4 mg/mL for E. faecalis (vancomycin-susceptible strains only) [4] . Interpretive criteria for MICs for intermediate susceptibility and resistance have not been determined because of a lack of data on daptomycinresistant strains [4] .
Using the recommended Ca 2+ concentrations, there have been no reports of initial clinical isolates resistant to daptomycin, and spontaneous resistance to daptomycin among staphylococci, enterococci, and pneumococci appears rare [18] . Two patients did develop infections with drug-resistant pathogens (S. aureus in one patient and E. faecalis in the other) that had documented increases in MICs of daptomycin during clinical trials (data on file, Cubist Pharmaceuticals) [2] . Mutants of S. aureus resistant to daptomycin can be isolated via serial passage and chemical mutagenesis, although some of these mutants appear to lose virulence or may not be as resistant in vivo as they appear to be in vitro [6] . Of interest, the voltage difference across the cytoplasmic membrane of tested drugresistant mutants was greater than that of the parent strain, further supporting the role of membrane potential dissipation as the mechanism of action of daptomycin [6] .
PHARMACOLOGY: PHARMACOKINETICS, PHARMACODYNAMICS, AND DOSING
Daptomycin exhibits linear pharmacokinetics with minimal accumulation (∼20%) in healthy volunteers at doses up to 6 mg/ kg, becoming slightly nonlinear at doses of 8 mg/kg in the area under the curve and trough concentrations [19] . The 24-h area under the concentration-time curve (AUC 0-24 ) values were 494 mg/h/mL, 747 mg/h/mL, and 1130 mg/h/mL for 4 mg/kg, 6 mg/ kg, and 8 mg/kg doses in healthy volunteers, with corresponding maximum plasma concentration (C max ) values of 57.8 mg/ mL, 98.6 mg/mL, and 133 mg/mL, respectively [4] . Its half-life ranged between 8 and 9 h, permitting dosing once per day. Its lipophilicity results in high protein binding (92%) that is independent of drug concentration, although it appears to decrease slightly in patients with renal dysfunction (i.e., those with a creatinine clearance of !30 mL/min), including patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis (CAPD) [4, 19] . Its low volume of distribution (∼0.1 L/kg) is due to its inability to cross cell membranes and its higher affinity for plasma proteins, as compared with tissue binding [19] . Approximately 78% of daptomycin is excreted via the kidney, two-thirds of which (∼52% of the total administered dose) is intact drug. It is not extensively metabolized, 90 , 0.5 mg/mL) described in Bozdogan and Applebaum [14] .
c Data is MIC 90 range for 3 isolates; see also Howe et al. [15] .
and any metabolites that are created do not appear functional or toxic [3] . Dosage adjustment is required in patients with creatinine clearances of !30 mL/min [4, 19] . A phase I study in patients with end-stage renal disease undergoing hemodialysis is underway. Daptomycin has several pharmacodynamic characteristics that make it an attractive alternative to currently available agents for treating drug-resistant gram-positive bacterial infections. In vitro studies demonstrate a rapid bactericidal effect against drug-resistant gram-positive pathogens [16] . It is active in a concentration-dependent manner and has a significant postantibiotic effect, allowing a once-daily administration regimen [3] .
The recommended dosage of daptomycin for treatment of skin and skin-structure infections is 4 mg/kg once every 24 h for patients with a creatinine clearance of у30 mL/min [4] . For patients with a creatinine clearance of !30 mL/min, including patients receiving hemodialysis and CAPD, the recommended dosage is 4 mg/kg every 48 h; it should be administered after hemodialysis on days when hemodialysis is performed, because ∼15% of the dose is removed by 4 h of hemodialysis [4] . No dosage adjustment is recommended for patients with mild-to-moderate hepatic dysfunction; there are no data for patients with severe hepatic dysfunction [4] .
CLINICAL STUDIES
The original phase II studies of daptomycin, performed by Eli Lilly, included patients with skin and soft-tissue infections (treated with 2 mg/kg q24h of daptomycin) and bacteremia (treated with 3 mg/kg q12h); both studies showed that treatment with daptomycin produced favorable outcomes [2, 3] . Overall, 285 patients received either daptomycin or conventional therapy [3] . Results in patients with skin or soft-tissue infections revealed clinical cure or improvement in 29 (96.6%) of 30 evaluable patients who were treated with daptomycin, compared with 37 (94.9%) of 39 evaluable patients who were treated with conventional therapy. Bacteriological cure was also documented, with similar results [3] . In 17 (89.5%) of 19 patients with gram-positive bacteremia, daptomycin therapy produced favorable clinical and bacteriological outcomes; the conventional therapy group was too small for meaningful comparison [3] . Other study results demonstrated fewer favorable responses among patients with deep-seated infections when daptomycin was administered at the lower dose; when administered at 3 mg/kg q12h, however, daptomycin therapy produced results in patients with endocarditis that appeared comparable to results in conventionally treated patients, although the numbers are too small for meaningful analysis [3] .
Phase III studies, initiated by Cubist Pharmaceuticals, included patients with cSSSIs, community-acquired pneumonia, urinary tract infections, and vancomycin-resistant enterococcal infections. The cSSSI studies included 1092 nonbacteremic patients from the United States, South Africa, Europe, and Australia, with patients randomized to receive either daptomycin 4 mg/kg q24h or a comparator (vancomycin q12h or a semisynthetic penicillin q.i.d.) [20] [21] [22] . Baseline patient characteristics were similar, as were adjunctive management interventions. Notably, the intention-to-treat (ITT) analysis revealed a 71% success rate in both the daptomycin arm and the comparator arm [4] . Results were also nearly identical in the modified ITT analysis population (which included only ITT subjects from whom a gram-positive organism was isolated at baseline), clinically evaluable population, and microbiologically evaluable population (data on file, Cubist Pharmaceuticals) [4. 20-22] . The success rate was also consistent in a subgroup analysis of patients with infections due to S. aureus (including methicillin-resistant strains), vancomycin-susceptible Enterococcus faecalis, and streptococci [4, [20] [21] [22] . Patients also tended to have a shorter duration of intravenous therapy with daptomycin than with the comparator (data on file, Cubist Pharmaceuticals) [21] .
Daptomycin was studied in 2 separate phase III trials for the treatment of community-acquired pneumonia, one of which enrolled patients from North America, western and eastern Europe, and Russia, and the other of which enrolled patients from South and Central America. The latter study was halted at 201 patients after the initial study was unblinded, revealing in the analysis of pooled data that daptomycin did not achieve the primary end point (noninferiority to ceftriaxone); consequently, daptomycin is not indicated for the treatment of this infection (data on file, Cubist Pharmaceuticals) [4] . Subset analysis of the North American and western European data revealed deceptively promising results, whereas analysis of the eastern European and Russian data demonstrated decreased cure rates with daptomycin therapy, a result consistent with other data that revealed low concentrations of daptomycin in the bronchial-alveolar lining fluid and lung parenchyma (data on file, Cubist Pharmaceuticals) [4] . The contradictory results appear to be strictly the result of differences in the practice of medicine; a higher percentage of patients in North America and Western Europe were pretreated (and arguably cured) with other antibiotics that were active against community-acquired pneumonia (the protocol allowed for 24 h of effective antibiotic therapy before initiation of daptomycin therapy) (data on file, Cubist Pharmaceuticals). A post hoc multivariate analysis revealed the absence of prior therapy with effective antibiotics as the only factor associated with poorer outcome. On the basis of these findings, daptomycin therapy is not appropriate for the treatment of pneumonia.
Two phase III studies have been terminated early because of difficulty enrolling subjects. The first, a trial designed to compare daptomycin therapy (administered alone or in combination with aztreonam) with ciprofloxacin therapy for complicated urinary tract infections due to known or suspected gram-positive organisms, enrolled ∼60 patients. After preliminary analysis, patients in both arms of the study had comparable results (data on file, Cubist Pharmaceuticals). The second, comparing daptomycin therapy with linezolid therapy for the treatment of infection due to vancomycin-resistant enterococci, was recently terminated after 50 patients were enrolled (data on file, Cubist Pharmaceuticals). Analysis of the latter study is not available; the small number of subjects will hinder analysis of both studies. Finally, a phase III study in which patients with S. aureus bacteremia and endocarditis are administered daptomycin at a dose of 6 mg/kg is actively enrolling patients.
SAFETY: ADVERSE REACTIONS AND DRUG-DRUG INTERACTIONS
Studies conducted before 1999 used daptomycin dosages of 3 or 4 mg/kg q12h; 2 of 5 subjects receiving the higher dose in a phase I study experienced a myopathy consisting of myalgias and extremity weakness along with elevations in serum creatine phosphokinase levels to 110 times the upper limit of normal [23] . These findings occurred after 7 and 11 days of dosing, respectively, and they resolved completely within days of discontinuing the study medication [23] . A patient who received 3 mg/kg q12h was found to have asymptomatic elevation of serum creatine phosphokinase levels to ∼5 times normal; levels returned to baseline values after discontinuation of therapy [2] . Animal studies demonstrated that the myopathy was specific to skeletal muscles [23] . The skeletal myopathy was associated with minimal degeneration that was associated with inflammation at high dosages; the inflammation did not further contribute to muscle damage, and there was regeneration without fibrosis [23] . The findings of animal studies further suggested that the skeletal myopathy correlated more closely with fre-quency of dosing than with the C max or the AUC 0-24 [23] , suggesting an association with high trough concentrations. These results, along with the pharmacodynamic data, support the switch to the dosing regimen of 4-6 mg/kg q24h investigated in the recent clinical trials. It should be emphasized that increased caution is required in treating patients with renal dysfunction because prolonged exposure to daptomycin may elicit myopathy; as noted, a phase I study in patients with end-stage renal disease is underway. Animal studies have also demonstrated that daptomycin is associated with peripheral nerve toxicity at high dosages (40 mg/kg per day); clinical trials in humans have not revealed any difference in neuropathy between daptomycin and its comparators [2] .
In the phase III cSSSI study, the incidence of adverse events associated with daptomycin did not differ from that associated with its comparators; notably, elevated creatine phosphokinase levels occurred in 2.8% of the patients who received daptomycin versus 1.8% of control patients [4] . However, given the toxicity identified in the early trials, it is recommended that serum creatine phosphokinase levels be monitored weekly and that the patient should be monitored for signs and symptoms of myopathy (e.g., muscle pain, tenderness, or weakness) [4] . Daptomycin therapy should be discontinued in patients who develop an otherwise unexplained myopathy with elevated creatine phosphokinase levels (у5 times the upper limit of normal or у1000 U/L) or an isolated marked increase in creatine phosphokinase levels (у10 times the upper limit of normal); patients with abnormal findings who do not meet these criteria should be monitored closely [4] . Although no drug-drug interactions have been identified, patients receiving therapy with HMG-CoA reductase inhibitors or other potentially muscletoxic agents should also be closely monitored [4] .
There is minimal hepatic metabolism of daptomycin, indicating that there should not be any clinically significant interactions with hepatically metabolized or hepatically cleared drugs [2, 3] . Aminoglycosides do not appear to markedly alter the pharmacokinetics of daptomycin or vice-versa; a small study of 6 healthy men did reveal a slight increase in the C max and AUC 0-24 of the daptomycin levels and a slight decrease in tobramycin levels, but none of the differences was statistically significant [2, 4] . Other small studies with healthy volunteers did not demonstrate any interactions with aztreonam, warfarin, simvastatin, or probenecid therapy [4] . On the basis of in vitro interaction studies, daptomycin therapy does not appear to adversely affect the antimicrobial activity of other agents [2] .
FDA-APPROVED INDICATIONS
Daptomycin is indicated for the treatment of complicated skin and skin-structure infections caused by susceptible strains of the following gram-positive organisms: S. aureus (including methicillin-resistant strains), S. pyogenes, S. agalactiae, S. dysgalactiae subspecies equisimilis, and Enterococcus faecalis (vancomycin-susceptible strains only) [4] . Daptomycin therapy is not indicated for the treatment of gram-positive bacterial pneumonia.
CONCLUSIONS
Daptomycin is a rapidly bactericidal antibiotic that targets drug-resistant gram-positive pathogens, is administered once daily, and has a promising safety profile. It joins quinupristindalfopristin and linezolid, both of which are recently approved agents that were developed to treat drug-resistant gram-positive bacterial infections. Although none of these agents appears to stand out from the others in terms of treating patients whose infections are caused by drug-resistant gram-positive pathogens, daptomycin does add to the armamentarium, and its unique characteristics may prove valuable in several clinical settings currently under investigation. Unfortunately, the clinical utility of daptomycin is currently limited as a result of both the availability of other more established antibiotics for its approved indication and its high cost. At $135 per 500 mg vial (average wholesale price), it is significantly more expensive than vancomycin (without evidence of improved clinical outcome), and at a dose of 4 mg/kg, its cost on average (depending on patient weight and drug stability factors) may be comparable to or slightly more than that of intravenous linezolid, albeit less than that of quinupristin-dalfopristin (table 1) . Finally, in our opinion, the promise of daptomycin lies not with the treatment of cSSSI at a dose of 4 mg/kg, but with the treatment of more-severe infections caused by drug-resistant pathogens (e.g., methicillin-resistant S. aureus endocarditis) at higher doses (e.g., 6 mg/kg). It may eventually prove to be the most effective agent in such a setting; however, use for such indications cannot be recommended until clinical efficacy and safety data become available.
